Table 4

Modeled clinical outcomes of life-time in lamivudine resistant CHB patient with rescue therapies
HBeAg status Positive Negative
Treatment No ADV ADV and LAM ENT TNV No ADV ADV and LAM ENT TNV
Cumulative incidence of compensated cirrhosis§ 0.51 0.49 0.39 0.47 0.31 0.80 0.76 0.59 0.76 0.53
Cumulative incidence of decompensated cirrhosis§ 0.20 0.19 0.14 0.18 0.12 0.33 0.30 0.22 0.31 0.21
Cumulative incidence of HCC§ 0.19 0.18 0.15 0.18 0.13 0.25 0.23 0.18 0.23 0.17
Cumulative mortality§# 0.41 0.38 0.30 0.37 0.25 0.64 0.58 0.42 0.59 0.41
Expected life-years 24.00 24.48 25.61 24.64 25.88 20.62 21.83 24.14 21.65 23.69
QALYs 8.77 9.25 10.58 9.43 11.17 7.76 8.64 10.48 8.51 10.36
Total cost ($) 9478.0 13011.9 21284.9 25387.0 27556.3 13097.2 16229.5 25552.8 27556.3 32270.9
Incremental cost ($)& - 3533.8 11806.9 15908.9 22452.4 - 3132.3 12455.6 14459.2 19173.8
Incremental QALYs& - 0.47 1.81 0.66 2.40 - 0.88 2.72 0.75 2.60
ICER - 7468.0 6531.7 24268.9 9359.8 - 3552.6 4571.7 19157.1 7370.4

§:Values are percentages, unless otherwise indicated.

#:Death is associated with hepatitis B.

&: “No treatment” was the baseline comparator.

†: ICER was calculated with the following equation: ICER=Incremental cost/Incremental QALYs. ICERs using the same 'no treatment' baseline.

Wu et al.

Wu et al. BMC Health Services Research 2012 12:385   doi:10.1186/1472-6963-12-385

Open Data